Psychometric properties of Sexual Function Questionnaire: evaluation of an Iranian sample

Afsaneh Khademi ¹², M.D., Ashraf Alleyassin ¹², M.D., Marzieh Agha-hosseini ¹², M.D., Nasrin Dadras¹, M.D., Allaleh Asghari Roodsari ³, M.D., Leila Tabatabaeefar ³, M.D., Mehrnoosh Amini¹, B.S.

- 1 Infertility Ward, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- 2 Vali-e-Asr Reproductive Health Research Center, Vali-e-Asr Hospital, Emam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- 3 Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Received: 31, December, 2005; accepted: 20, April, 2006

Abstract

Background: Female sexual dysfunction (FSD) is a real problem that affects 25-63% of women. There is no valid Persian version of sexual function questionnaire (FSQ).

Objectives: The aim of this study was to test the reliability and validity of Persian version of sexual function questionnaire.

Materials and Methods: In this cross-sectional study, 547 women were questioned by Persian version of SFQ. Factor analysis produced five domains of female sexual function. Internal consistency, test-retest reliability, and discriminant validity were calculated.

Results: Five-factor structure accounted for 63% of the variance. Arousal-orgasm domain was as same as arousal-sensation, arousal-lubrication, and orgasm domains of the original version. Enjoyment-desire domain was similar to enjoyment and desire domains except one question. Pain and partner domains were consistent with original domains. Internal consistency, test-retest reliability, and discriminant validity were reasonable in Persian version of SFO.

Conclusion: Persian version of SFQ is almost valuable and reliable to use for Iranian population with exception of one question. Results of the omitted question from enjoyment domain should interpret separately as unusual sex domain.

Key words: Sexual function questionnaire, Female sexual dysfunction, Persian version

Introduction

Female sexual dysfunction (FSD) is a real problem that affects a significant number of populations. Increased awareness of this problem in the medical community will lead to further research in female sexual dysfunction, and improved treatment (1). FSD is highly prevalent, occurring in 25–63% of women (2). A meta-analysis estimated prevalence of orgasmic disorders to be 7–10% (3).

Although the best method of screening and diagnosis of FSD is structured interview by several designed questionnaires. Some of these tests are designed to address one specific aspect of FSD such as ease in arousal or level of sexual desire (4-5). The Sexual Activity Questionnaire was designed to

Correspondence Author:

Dr. Afsaneh Khademi, Vali-e-Asr Reproductive Health Research Center, Emam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

E-mail: afkhademi@sina.tums.ac.ir

assess the impact of cancer treatments on sexual function (6). The Sexual Interaction Survey and the Sexual Interaction System Scale have a dyadic focus (7-8). More multidimensional measures include the Derogatis Sexual Function Inventory (DSFI), a collection survey of sexual attitude, experience, and satisfaction, and the Brief Index of Sexual Functioning for Women (9-10).

The more recently developed Female Sexual Function Index has already been used in several trials (11). Now there questionnaires in relation to sexual dysfunction. The Sexual Quality of Life-Female (SQOL-F) questionnaire has been developed to assess the impact of female sexual dysfunction (FSD) on a woman's sexual quality of life. SQOL-F items were developed through interviews with 82 women. The SQOL-F showed good psychometric properties: convergent validity. discriminate validity, and test-retest reliability. However, the SQOL-F sensitivity should be confirmed (12). Sexual Function Questionnaire (SFQ) is a self- reported outcomes measure of female

sexual function (13). The SFQ addresses all aspects of the sexual response cycle and pain, incorporating the more recently developed classifications (14).

In our knowledge, there is no valid Persian version of sexual inventory. The aim of this study was to translate SFQ in Persian (Iranian language) and test the reliability and validity of Persian version of SFQ.

Materials and Methods

From March to October 2005, in total 547 women participated in a cross-sectional study. The participants included 73 pregnant subjects, 167 infertile patients, 258 normal subjects (university students or subjects visited the contraception clinic) and 49 patients visited for gynecological problems. The study was approved by the Ethical Committee of Tehran Medical Sciences University. Institutional Review Board approval was obtained before commencing the trial as well. All patients and their husbands gave their written permission.

The main characteristics of the studied population are described in Table I. A questionnaire asked about female and her partner age, duration of marriage, level of education of female and her partner, and female occupation. All patients were initially evaluated for satisfaction of sexual function by asking a single question: 'How much is your satisfaction rate from your sexual function?' The answer estimated by a self-rating scale, which was shown in the demographic questionnaire.

Table I. Characteristics of participants who fill out the Persian version of Sexual Function Questionnaire

	$Mean \pm SD$	
	(minimum-maximum)	
Female age (years)	$27 \pm 6.2 (16-48)$	
Duration of marriage (years)	$5.7 \pm 5.3 \ (0*-30)$	
Husband age (years)	$31.5 \pm 6.5 (19-63)$	
Female education	Number (%)	
Primary school	71 (13%)	
Secondary school	111 (20.3%)	
High school	69 (12.6%)	
Diploma	222 (40.6%)	
University education	74 (13.5%)	
Husband education		
Primary school	71 (13%)	
Secondary school	100 (18.3%)	
High school	63 (11.5%)	
Diploma	204 (37.3%)	
University education	109 (19.9%)	
Female occupation		
Housewife	430 (78.6%)	
Occupied	117 (21.4%)	

^{*} Duration of marriage was ≤ 6 months

Self-rating scale was scored 0 to 10 in a positive regression. Due to rules of ethics, patients with score <5 were offered sexologist visit for confirmation of diagnosis and treatment if needed. We put the open question about FSD on demographic questionnaire to compare the scores obtained by the main questionnaire of sexual dysfunction in patients complained from FSD with normal subjects.

Ouestionnaire

A questionnaire named Sexual Function Questionnaire-version 2 (SFQ-V2) with 7 domains and 26 items was used. The 7 domains of SFQ are consisting of 26 items. These 7 domains included: desire (Q1–4, 13, 26; score range 5–31), arousal-sensation (Q7–10; score range 4–20), arousal-lubrication (Q11–12; score range 2–10), orgasm (Q22–24; score range 3–15), enjoyment (Q6, 14, 18, 19, 21, 25; score range 6–30), pain (Q15, 16, 20; score range 2–15), and partner relationship (Q28, 29; score range 2–10). (Table II) (13).

The standard "forward-backward" procedure was applied to translate the questionnaire from English into Persian. Two independent English experts translated the items, two others translated the response categories, and a provisional version was provided. Careful cultural adaptation of the final version was provided. Subsequently it was back translated into English and checked by another two English experts to confirm the similarity of the translated items to the original questionnaire.

Factor analysis

Factor analysis attempts to identify underlying variables, or factors, which explains the pattern of correlation within a set of observed variables. Factor analysis is often used in data reduction to identify a small number of factors that explain most of the variance observed in a much larger number of manifest variables. In this study, factor structure of the questionnaire was done. Criteria for identification of domains and items to be retained on factor analysis were factors with eigenvalues >1.0 and items with factor loading >0.4, and Pearson's correlation coefficient R value < 0.3. If the Cronbach's alpha (α) value was acceptable (above 0.6 to 0.7) and could not be improved by the removal of items, this was acknowledged as a domain (15).

Table II. Comparison of factor analysis of SFQ-V2 items between 547 Iranian subjects and Quirk et al. study (Factor analysis,

principal components and varimax rotation)

	Factor 1 Arousal-sensation, lubrication and Orgasm	Factor 2 Desire and Enjoyment	Factor 3 Partner	Factor 4 Pain	Factor 5 Unusual sex
Q1: Frequency of pleasurable thoughts about SA ^a	8	67 (75)	-	_	_
Q2: Frequency of wanting to be touched		67 (79)	_	_	_
Q3: Frequency of wanting to take part in SA		75 (78)	-	_	-
Q4: How often initiated SA		72 (69)	-	_	-
Q6: Enjoyment of touching by partner		56 (48,50)	-	_	-
Q7: Frequency of warmth during SA	70 (80)	-	-	-	-
Q8: Amount of warmth during SA	74 (80)	-	-	-	-
Q9: Frequency of pulsating during SA	75 (79)	-	-	-	-
Q10: Amount of pulsating during SA	73 (76)	-	-	-	-
Q11: Frequency of vaginal wetness during SA	67 (85)	-	-	-	-
Q12: Amount of vaginal wetness during SA	74 (78)	-	-	-	-
Q13: Frequency of penetrative SA	46	44 (50)	-	-	-
Q14: Enjoyment of penetrative SA	44	67 (51)	-	-	-
Q15: Frequency of pain during SA	-	-	66	45 (93)	-
Q16: Amount of pain during SA	-	-	-	82(87)	
Q18: Enjoyment of nonpenetrative SA	-	-	-	-	75
Q19: Emotional closeness with partner during SA	-	62 (58)	-	-	-
Q20: Worry about pain during SA	-	-	-	55(90)	-
Q21: Feeling good when sexually active	53 (58)	60	-	-	-
Q22: Frequency of orgasms	55 (70)	48	-	-	-
Q23: How pleasurable were orgasms	57 (80)	48	-	-	-
Q24: Ease of orgasm	53 (70)	-	-	-	-
Q25: Confidence as sexual partner	-	55 (43,55)	-	-	-
Q26: How often looked forward to SA	-	65 (78)	-	-	-
Q28: Worry partner will seek other relationship	-	-	89 (73)		-
Q29: Worry about partner's negative feelings	-		88 (91)		

Note: a SA, sexual activity.

Values have been multiplied by 100 and rounded to the nearest integer. Only values >0.4 are shown.

Internal consistency

Internal consistency of the questionnaire was assessed by Cronbach's alpha coefficient and values equal to or greater than 0.70 was considered satisfactory (16). Internal consistency, a correlational determination of the goodness of fit of the items within a domain, is measured on a scale of 0–1. In our study, we watched 49 couples who had undergone treatment with Sildenafil citrate (Viagra; Pfizer, India) for FSD. Forty-four normal subjects fill the questionnaire at baseline and 4-8 weeks later. We used data of whole sample and the data of before-after treatment of these two groups to find out internal consistency.

Reliability

To determine test-retest reliability, Pearson's correlations were used. Data of 44 normal participants were used to determine test-retest reliability.

Validity

To determine validity of the questionnaire discriminant validity was assessed. Discriminant validity refers to the ability of items to show clear, statistically significant differences between populations known to differ on aspects of function. In the studies used other questionnaires, there was a significant difference between the baseline mean SFQ domain scores of patients with FSD compared with those of women without FSD (13, 17-20). In our study, mean values of domains were compared between patients complained from FSD and normal participants.

Results are presented as means \pm SD or percentile. Statistical analysis was conducted using factor analysis, reliability analysis, and Student's *t*-test as appropriate. The significant level was set at p-value less than 0.05. Data analysis was carried out using Statistical Package for Social Science (SPSS 11.0; Chicago, IL).

^{-:} indicates a factor score of <40.

^{():} Quirk et al. study data

Results

The study was carried out on 547 subjects. Their characteristics are shown in Table 1. A total of 227 (42%) participants had a FSD score of <5, found out by self-rating scale. Principal components analysis with varimax rotation was conducted in order to identify possible new domains (Table II). This method was used by authors who introduced the questionnaire (13). By this way, Quirk *et al* (13) found seven domains. To compare their domains with our study, the factor scores of Quirk *et al* study are included in parentheses in Table II. We found five domains in our analysis.

Questions entered in first domain were similar to questions located in arousal-lubrication, arousal-sensation, and orgasm domains of Quirk *et al* study (13). Therefore, this domain was named arousal-orgasm domain. Items located in second domain were as items of enjoyment and desire domains of Quirk *et al* study. The exception was question 18: Over the last 4 weeks, in general, how much did you enjoy sexual activity without penetration (e.g., masturbation and oral sex)?

Enjoyment-desire was the suitable name for this domain. In total 72.2% of patients responded to

question 18 with negative slant. They answered "Not enjoyable" to this question.

Pain and partner domains were as same as original article. The last domain consisted question 18. Because of concept of this question, we named it as unusual sex domain. Five-factor structure accounted for 63% of the variance.

Internal consistency of Persian version of SFQ ranged from 0.71 to 0.91 in total sample. Values were similar between the patients complained from FSD and normal samples. Baseline values were comparable with values obtained from second questionnaire administered after treatment or after 4-8 weeks (Table III).

The item test-retest reliability showed fair scaling results for the normal samples. *R* values for Pearson's correlation coefficient for individual domains were as follows; 0.9 for arousal-orgasm domain, 0.85 for enjoyment-desire domain, 0.81 for pain domain, 0.96 for partner domain, and 0.91 for unusual sex domain.

There was a significant difference between the baseline mean SFQ domain scores of patients with FSD complaint compared with those of women without FSD complaint (except for pain and unusual sex) (p < 0.000) (Table IV).

Table III: Internal consistency of Persian version of SFQ-V2 in subjects with and without FSD

·		· ·		Internal consistency non-FSD (44 subjects)		
			Baseline	End of treatment	Baseline	After 4-8 weeks
Arousal-sensation, lubrication and Orgasm	9	0.90	0.78	0.66	0.81	0.82
Desire and Enjoyment	11	0.90	0.87	0.85	0.83	0.73
Partner	2	0.91	0.70	0.68	0.67	0.74
Pain	3	0.71	0.93	0.90	0.83	0.87

Table IV: Discriminant validity of Persian version of SFO-V2 in women with and without complaint of FSD

Domain	FSD	Non-FSD	p value
Arousal-sensation, lubrication and Orgasm	20.7 ± 6.6	25 ± 8.5	<0.000
Desire and Enjoyment	31.5 ± 8.5	35.7 ± 8.7	< 0.000
Partner	4.5 ± 2.6	6.8 ± 3.5	< 0.000
Pain	8.28 ± 2.01	8.49 ± 2.92	NS
Unusual sex	1.44 ± 0.79	1.37 ± 0.71	NS

Note: NS= not significant

Discussion

The original version of SFQ is a sexual questionnaire with excellent internal consistency, moderate to good reliability, excellent discriminant validity, longitudinal validity, and construct validity (13).

In factor analysis of Persian version of SFQ we found five domains. These domains included arousal-orgasm (Q7–12, Q22–24; score range 9–45), enjoyment-desire Q1–4, 6, 13-14,19,21, 25-26; score range 10–56), pain (Q15, 16, 20; score range 2–15), partner relationship (Q28, 29; score range 2–10), and unusual sex (Q18; score range 1-5).

All items and domains had reasonable correlation with their own dimension. However, as only one item of enjoyment domain produced a significantly different correlation, the results were considered satisfactory (20). Cronbach's alpha values being above the 0.70 threshold for all domains indicated excellent internal consistency reliability. *R* values for Pearson's correlation coefficient of 0.81 to 0.91 for individual items is a reasonable result.

In comparison of patients with FSD complaint and normal subjects, mean score of all domains except pain and unusual sex domain were significantly higher in patients with problem. Other studies compared definitely diagnosed FSD with normal subjects, found out the significantly higher scores in women with FSD (11, 17-20). Samples of Quirk et al (13) study displayed some type of sexual dysfunction conditions for at least 6 months prior to the study. In contrast, the majority of our samples were recruited from normal population. It seems that concept of organic disease was matched more than FSD to pain symptom. Participants with pain in their sexual function did not point it out as FSD. So, the mean score of pain domain did not significantly differed between the two groups.

The response to item unusual sex domain was negative in 72.2% of participants. This makes the result of comparing means to be unreliable (Table IV).

In Persian version of SFQ, the items of arousal-sensation, arousal lubrication, and orgasm domain in original version were categorized in one factor. As the original domains figured out separate items in sexual dysfunction, it is reasonable to assume the original domains. The domain named enjoyment-desire was similar to two domains of enjoyment and desire domain of the original version. Question 18 [Over the last 4 weeks, in general, how much did you enjoy sexual activity without penetration? (e.g., masturbation and oral sex)] had different results. The results of question 18 should discuss with caution in

Iranian population. This is due to different cultural insight in eastern countries. Question 18 can be analyzed separately as unusual sex factor.

It seems that with exception of results of question 18, Persian version of SFQ has reasonable validity and reliability to use for Iranian population. Results of question 18 should interpret separately. The score ranges of Quirk et al study were based on their database of subjects. One study emphasized that the scores may be subject to alteration as the database increases (21). In using Quirk et al scores, only score of domain enjoyment should be adjusted in the Persian version. By subtracting question 18 from the list of questions in this item we can calculate the scores again with five questions. Maximum score of this item change from 30 to 25 in Persian version. Therefore, the 15% decrease in total score can be manipulated to all scores in this domain. Scores 6-16 indicates high probability of FSD in enjoyment domain. This score will change to 5-13 in Persian version. Score of borderline probability of normal sexual function, which was 17-22 in original version, will change to 14-18. Score of 23-30, which is indicative of high probability of normal sexual dysfunction, will change to 19-25 in Persian version of SFQ. Future studies on Iranian samples can disclose the scores more correctly.

Conclusion

We emphasize that there are a number of meaningful relationships between sexual function and socio-cultural variables, which were not mentioned here. Thus, in future studies, other questions in relation to socio-cultural variables should be included and evaluated specifically for Iranian subjects.

Acknowledgements

We gratefully acknowledge the participation of the infertility ward staff of Shariati Hospital: Nahid Abbassi Moaff, Sedeegheh Amrollahi and Zahra Rezaian Movahed. This study was supported by Valie-Asr Reproductive Health Research Center, Tehran University of Medical Sciences.

References

- 1. DeUgarte CM, Berman L, Berman J. Female Sexual Dysfunction—from Diagnosis to Treatment. *Sexuality, Reproduction & Menopause* 2004;2:139-145.
- 2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. *JAMA* 1999;281:537-44.

- 3. Simons JS, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. *Arch Sex Behav* 2001;30:177-219.
- 4. Hoon EF, Joon PW, Wincze JP. An inventory for the measurement of female sexual arousability: The SAI. *Arch Sex Behav* 1976;5:269-274.
- 5. Spector IP, Carey MP, Steinberg L. The sexual desire inventory: development, factor structure, and evidence of reliability. *J Sex Marital* Ther 1996;22:175-190.
- 6. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: a measure of women's sexual functioning. *Qual Life Res* 1996;5:81-90.
- 7. LoPiccolo J, Steger JC. The sexual interaction inventory: a new instrument for assessment of sexual dysfunction. *Arch Sex Behav* 1974;3:585-595.
- 8. Woody JD, D'Souza HJ. The Sexual Interaction System Scale: a new inventory for assessing sexual dysfunction and sexual distress. *J Sex Marital Ther* 1994;20:210-228.
- 9. Derogatis LR, Melisaratos N. The DSFI: a multidimensional measure of sexual functioning. *J Sex Marital Ther* 1979;5:244-81.
- 10. Mazer NA, Leiblum SR, Rosen RC. The brief index of sexual functioning for women (BISF-W): a new scoring algorithm and comparison of normative and surgically menopausal population. *Menopause* 2000;5:350-363.
- 11. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, *et al.* The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 2000; 26:191-208.
- 12. Symonds T, Boolell M, Quirk F. Development of a questionnaire on sexual quality of life in women. *J Sex Marital Ther* 2005;31:385-397.
- 13. Quirk FH, Heiman JH, Rosen RC, Laan E, Smith MD, Boolell M. Development of a Sexual Function

- Questionnaire for Clinical Trials of Female Sexual Dysfunction. *J Womens Health Gend based Med* 2002; 11:277-289
- 14. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, *et al.* Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. *J Urol* 2000;163:888-893.
- 15. Bullinger M, Power MJ, Aaronson NK, Cella DF, Anderson RT. Creating and Evaluating Cross-Cultural Instruments. in: Quality of Life and Pharmacoeconomics in Clinical Trials. Edited by Spilker B. Philadelphia: Lippincott-Raven; 1996;659-668.
- 16. Nunnally JC, Bernstien IH. Psychometric Theory. 3rd edition. New York:McGraw-Hill;1994.
- 17. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. *J Sex Marital Ther* 2005;31:1-20.
- 18.Matzaroglou C, Assimakopoulos K, Panagiotopoulos E, Kasimatis G, Dimakopoulos P, Lambiris E. Sexual function in females with severe cervical spinal cord injuries: a controlled study with the Female Sexual Function Index. *Int J Rehabil Res* 2005;28:375-377.
- 19. Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. *J Sex Marital Ther* 2003;29:39-46.
- 20. Derogatis L, Rust J, Golombok S, Bouchard C, Nachtigall L, Rodenberg C, *et al.* Validation of the profile of female sexual function (PFSF) in surgically and naturally menopausal women. *J Sex Marital Ther* 2004;30:25-36.
- 21. De la Loge C, Sullivan K, Pinkney R, Marquis P, Roux C, Meunier PJ. Cross-cultural validation and analysis of responsiveness of the QUALIOST: QUAlity of Life questionnaire In OSTeoporosis. *Health Qual Life Outcomes* 2005; 3:69.